The BioCentury Show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
The BioCentury Show
Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, according to Syncona CEO Chris Hollowood.
Hollowood spoke on The BioCentury Show with Editor in Chief Simone Fishburn about how discovery is evolving, why causal biology has been stuck in a loop of circularity, and where the U.K. investor is headed. He also discussed the firm’s approach to gene therapy investments, how it is surmounting the field’s challenges and Syncona’s pivot last year, with a portfolio shift from 25% to over 85% clinical-stage companies.
View full story: https://www.biocentury.com/article/659341
#CausalBiology #GeneTherapy #BiotechInvesting #DrugDiscovery #ClinicalStage
00:00 - Introduction
01:06 - Rational Target Discovery
16:48 - Gene Therapy
23:15 - Syncona’s Strategy
.jpg)
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
